|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Neoadjuvant bevaci-zumab, oxaliplatin, 5 -fluorouracil, and radiation for rectal cancer显示文摘 | Dipetrillo T Pricolo V Lagares-garcia J | 2012 | Int J Radiat Oncol Biol Phys2012，82，1： | 1 |
| 2 | Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity显示文摘 | SAFRAN H SUNTHARALINGAM M DIPETRILLO T | 2008 | Int J Radiat Oncol Biol Phys2008，70，2： | 1 |
| 3 | Limited resection for non - small cell lung cancer : observed local control with implantation of ^125I brachytherapy seeds显示文摘 | LEE W DALY B D DIPETRILLO T A | 2003 | Ann Thorac Surg2003，75，： | 1 |
| 4 | Trastuzumab,paclitaxel, cisplatin, and adiation for adenocarcinoma of the esophagus : a phase I study 显示文摘 | SAFRAN H DIPETRILLO T NADEEM A | 2004 | Cancer Investigation2004，22，5： | 1 |
| 5 | Long-term follow-up of aprospective policy of margin directed radiation dose escalation in breastconserving therapy显示文摘 | Neuschatz AC DiPetrillo T Safaii H | 2003 | Cancer2003，97，1： | 1 |
| 6 | Cetuximab with concurrent ehemoradiation for esophagogastrie cancer: assessment of toxicity 显示文摘 | Safran H Suntharalingam M Dipetrillo T | 2008 | Int J Radiat Oncol Biol Phys2008，70，2： | 1 |
| 7 | Optimal radiotherapy for prostate cancer:predictions for conventional external beam,and brachytherapy form radiobiologic models显示文摘 | King C R DiPetrillo T A Wazer D E | 2000 | Int J Radiat Oncol Biol Phys2000，46，： | 1 |
| 8 | Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity 显示文摘 | Safran H Suntharalingam M Dipetrillo T | 2008 | Int J Radiat Oncol Biol Phys2008，70，2： | 1 |
| 9 | Phase I/lI study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma显示文摘 | Safran H Dipetrillo T Akerman P | 2007 | Int J Radiat Oncol Biol Phys2007，67，2： | 1 |
| 10 | Phase I / I1 study of trastuzumab, paelitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma 显示文摘 | Safran H DiPetrillo T Akerman P | 2007 | Int J Radiat Oneol Biol Phys2007，67，2： | 1 |
| 11 | Cetuximab with concurrent ehemoradiation for esophagogastric cancer: assessment of toxicity 显示文摘 | Safran H Suntharalingam M Dipetrillo T | 2008 | Int J Radiat Oncol Biol Phys2008，70，2： | 1 |
| 12 | Paclitaxel poliglumex(PPX-Xyotax) and concurrent radiation for esophageal and gastric cancer:a phase Ⅰ study显示文摘 | Dipetrillo T Milas L Evans D | 2006 | Am J Clin Oncol2006，29，4： | 1 |
| 13 | Long-term follow- up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy 显示文摘 | Neuschatz AC Dipetrillo T Safaii H | 2003 | Cancer2003，97，1： | 1 |
| 14 | Safety and immunogenicit y of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers显示文摘 | Tibbetts T Kleanthous H | 1999 | Vaccine1999，18，56： | 1 |
| 15 | Trastuzumab, paclitaxel,cisplatin, and radiation for adenocarcinoma of the esophagus: a phase Ⅰ study显示文摘 | Safran H DiPetrillo T Nadeem A | 2004 | Cancer Invest2004，22，5： | 1 |
| 16 | Phase I/II study oftrastuzumab, paclitaxel, cisplatin and radiation for locally ad- vanced, HER2 overexpressing, esophageal adenocarcinoma 显示文摘 | Safran H Dipetrillo T Akerman P | 2007 | Int J Radiat Oncol Biol Phys2007，167，2： | 1 |
| 17 | Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy显示文摘 | Neuschatz AC DiPetrillo T Safaii H | 2003 | Cancer2003，97，1： | 1 |
| 18 | Neoadjuvant paclitaxel poliglumex,cisplatin,and radiation for esophageal cancer: a phase 2 trial显示文摘 | Dipetrillo T Suntharalingam M Ng T | 2012 | Am J Clin Oncol2012，35，1： | 1 |
| 19 | Cetuximab with concurrent chemoradiation for esophagogastric cancer:assessment of toxicity显示文摘 | Safran H Suntharalingam M Dipetrillo T | 2008 | Int J Radiat Oncol Biol Phys2008，70，2： | 1 |
| 20 | Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy显示文摘 | Neuschatz AC Dipetrillo T Safaii H | 2003 | Cancer2003，97，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员